dc.contributor.author |
Schellack, Natalie
|
|
dc.contributor.author |
Truter, A.
|
|
dc.contributor.author |
Ntuli, P.N.
|
|
dc.contributor.author |
Mokwele, N.
|
|
dc.contributor.author |
Mogale, K.
|
|
dc.contributor.author |
Esterhuizen, A.
|
|
dc.date.accessioned |
2022-07-29T06:47:57Z |
|
dc.date.available |
2022-07-29T06:47:57Z |
|
dc.date.issued |
2021-08 |
|
dc.description.abstract |
Asthma is a chronic inflammatory disease that causes hyper-responsiveness of the bronchial tree, with reversible airflow obstruction. The
condition places a significant burden on our healthcare system. Chronic asthma can cause remodelling of the airway. Patients suffering from
asthma should be aware of the signs and symptoms thereof, as well as the factors that can precipitate an asthmatic attack. Asthma is mostly
classified as either acute or chronic; the diagnosis of asthma is based on identifying both a characteristic pattern of respiratory symptoms and
variable expiratory airflow limitation. Treatment is based on how the patient presents and includes bronchodilators, inhaled corticosteroids
and mast cell stabilisers. This article provides an overview of the diagnosis, characterisation and treatment of asthma. |
en_US |
dc.description.department |
Pharmacology |
en_US |
dc.description.uri |
http://www.sapj.co.za |
en_US |
dc.identifier.citation |
Schellack, N., Truter, A., Ntuli, P. N. et al. 2021, 'A 2021 update : approach to asthma management in adults', SA Pharmaceutical Journal, vol. 88, no. 4, pp. 17-24, doi : 10.520/ejc-mp_sapj_v88_n4_a6. |
en_US |
dc.identifier.issn |
2220-1017 (online) |
|
dc.identifier.issn |
2221-5875 (print) |
|
dc.identifier.other |
10.520/ejc-mp_sapj_v88_n4_a6 |
|
dc.identifier.uri |
https://repository.up.ac.za/handle/2263/86581 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Medpharm Publications |
en_US |
dc.rights |
Medpharm Publications. This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License. |
en_US |
dc.subject |
Asthma |
en_US |
dc.subject |
Bronchodilator |
en_US |
dc.subject |
Inhaled corticosteroid |
en_US |
dc.subject |
β-agonist |
en_US |
dc.subject |
Spirometry |
en_US |
dc.subject |
Peak expiratory flow |
en_US |
dc.subject |
Short-acting β2-agonist (SABA) |
en_US |
dc.subject |
Long-acting β2-agonist (LABA) |
en_US |
dc.title |
A 2021 update : approach to asthma management in adults |
en_US |
dc.type |
Article |
en_US |